July 29, 2013

Guideline Title

The Clinical Pharmacogenetics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Bibliographic Source(s)

Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M, Clinical Pharmacogenetics Implementation Consortium (CPIC). The Clinical Pharmacogenetics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012 Jul;92(1):112-7. [41 references] PubMed External Web Site Policy

Guideline Status

This is the current release of the guideline.

The clinical pharmacogenomics implementa... [Clin Pharmacol Ther. 2012] - PubMed - NCBI

2012 Jul;92(1):112-7. doi: 10.1038/clpt.2012.57. Epub 2012 May 23.

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, Krauss RM, Roden DM, Feng Q, Cooper-Dehoff RM, Gong L, Klein TE, Wadelius M, Niemi M; Clinical Pharmacogenomics Implementation Consortium (CPIC).

Source

Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA. russell.a.wilke@vanderbilt.edu

Abstract

Cholesterol reduction from statin therapy has been one of the greatest public health successes in modern medicine. Simvastatin is among the most commonly used prescription medications. A non-synonymous coding single-nucleotide polymorphism (SNP), rs4149056, in SLCO1B1 markedly increases systemic exposure to simvastatin and the risk of muscle toxicity. This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly.